Video

Dr. Foley Discusses Guidelines for Cancer Pain Management

Dr. Kathleen Foley, from Memorial Sloan-Kettering Cancer Center, Discusses the World Health Organization Guidelines for Cancer Pain Management.

Kathleen M. Foley, MD, an Attending Neurologist in the Pain & Palliative Care Service at Memorial Sloan-Kettering Cancer Center, believes that one of the most important advances in the quality of care provided to patients with cancer pain were the guidelines developed by the World Health Organization (WHO) in the 1980s.

Foley notes that these guidelines made an enormous difference in the way that cancer pain was managed, throughout the world. In general, the guidelines dealt with the use of pharmacologic agents, as the mainstay approach.

However, as time progressed, it became clear that managing pain in cancer patients didn’t just involve pharmaceuticals. This type of pain is more complex, Foley explains, and requires a larger team of individuals working together to improve pain for patients with cancer.

<<<

View more from the 2012 MASCC International Symposium

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD